Intro

This chapter discusses a biopharmaceutical company's breakthroughs in immuno-oncology, particularly their recent FDA submission for a treatment targeting recurrent respiratory papillomatosis. The use of gorilla adenovectors for genetic delivery is also explored, showcasing their potential benefits for future therapies.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

Get the app